A Significant Development in Cancer Treatment
A groundbreaking achievement has been made in cancer treatment.
Chimeric Antigen Receptor (CAR) T-cell therapy has previously been noted for its effectiveness in treating blood cancers, such as specific leukemias and lymphomas. However, its application has been somewhat limited in the realm of solid tumors—until now.
Recently, a 3-year-old boy diagnosed with a chemotherapy-resistant cancer that had spread from his liver to his lungs, and possibly even his bones, was declared free of cancer after receiving just two doses of this experimental therapy.
The findings, which were shared by researchers from Texas Children’s Hospital, Baylor College of Medicine, and Seattle Children’s Hospital, were published this month in the New England Journal of Medicine.
The young patient was suffering from hepatoblastoma, a frequent type of liver cancer in children, and had a tumor that measured a staggering 4.4 × 3.8 × 2.8 inches.
Even after several rounds of chemotherapy and surgery aimed at tumor removal, the cancer persisted and metastasized to his lungs, with indications it had also spread to his bones.
In response, doctors introduced CAR T-cell therapy, which entails taking a patient’s white blood cells (T cells) and genetically modifying them to target and fight cancer.
Following two doses of the experimental GPC3-CAR therapy over a span of eight weeks, the boy showed no remaining signs of the disease, and this remained true even after a year—marking a complete regression.
“This study indicates that these novel CAR T cells may be a safe and effective option for hepatoblastoma and emphasizes the necessity for further evaluation in patients with GPC3+ solid tumors,” said study co-author and pediatric oncologist Andras Heczey.
Liver cancer is the third-leading cause of cancer-related deaths worldwide, and hepatoblastoma usually relies on radiation and surgery to eradicate cancerous cells and tumors—approaches that aren’t always effective.
While CAR T-cell therapy represents a significant advancement, it is currently only FDA-approved for specific types of leukemias, lymphomas, and multiple myeloma.
Treating solid tumors with this therapy has posed challenges due to a resistant chemical shield that obstructs and destroys immune cells.
Moreover, tumor cells often camouflage themselves as healthy cells, leveraging neighboring healthy cells (like fibroblasts and regulatory immune cells) to create protective barriers.
This breakthrough follows earlier findings suggesting that T-cell therapy was effective against aggressive brain tumors in children.
Although CAR T-cell therapy for liver cancer was trialed in a single patient and more research is needed to assess both its safety and effectiveness, the initial results certainly seem encouraging.
Further investigation of the GPC3-CAR treatment is ongoing as part of the CARE study, which is the first human trial of this experimental CAR T-cell therapy for pediatric patients dealing with recurrent solid tumors, conducted at Baylor College of Medicine.
